Investigating to Optimal Ratio between Drug and Co-Former in Co-Amorphous Systems

Research output: Contribution to journalJournal articlepeer-review

Standard

Investigating to Optimal Ratio between Drug and Co-Former in Co-Amorphous Systems. / Rades, Thomas.

In: Proceedings, Vol. 78, No. 1, 27, 2021.

Research output: Contribution to journalJournal articlepeer-review

Harvard

Rades, T 2021, 'Investigating to Optimal Ratio between Drug and Co-Former in Co-Amorphous Systems', Proceedings, vol. 78, no. 1, 27. https://doi.org/10.3390/IECP2020-08764

APA

Rades, T. (2021). Investigating to Optimal Ratio between Drug and Co-Former in Co-Amorphous Systems. Proceedings, 78(1), [27]. https://doi.org/10.3390/IECP2020-08764

Vancouver

Rades T. Investigating to Optimal Ratio between Drug and Co-Former in Co-Amorphous Systems. Proceedings. 2021;78(1). 27. https://doi.org/10.3390/IECP2020-08764

Author

Rades, Thomas. / Investigating to Optimal Ratio between Drug and Co-Former in Co-Amorphous Systems. In: Proceedings. 2021 ; Vol. 78, No. 1.

Bibtex

@article{2c417abf283843b0896ab12eecf163dd,
title = "Investigating to Optimal Ratio between Drug and Co-Former in Co-Amorphous Systems",
abstract = "Most new low molecular weight chemical entities in pharmaceutical developments suffer from a low aqueous solubility, making oral delivery challenging. Despite the numerous formulation efforts that can be investigated, research especially on amorphous drugs and formulations appears to be a useful approach. Whilst few drugs can be converted to an amorphous form on their own, due to their physical stability, the use of amorphous solid dispersions, i.e., the dissolution of drug molecules into (amorphous) polymers is increasingly used. However, certain shortcomings of these polymers based amorphous solid dispersions, such as a low drug load and a usually high hygroscopicity, still necessitate the investigation of alternative approaches. One such approach is the use of co-amorphous systems, i.e., the combination of initially crystalline low molecular weight drugs and excipients. Usually, here, a 1:1 molar ratio is used, but this may not be the optimal mixing ratio. In this presentation, work on investigating the optimal ratio between drug and co-former will be presented and critically discussed.",
author = "Thomas Rades",
year = "2021",
doi = "10.3390/IECP2020-08764",
language = "English",
volume = "78",
journal = "Proceedings",
issn = "2504-3900",
publisher = "MDPI",
number = "1",

}

RIS

TY - JOUR

T1 - Investigating to Optimal Ratio between Drug and Co-Former in Co-Amorphous Systems

AU - Rades, Thomas

PY - 2021

Y1 - 2021

N2 - Most new low molecular weight chemical entities in pharmaceutical developments suffer from a low aqueous solubility, making oral delivery challenging. Despite the numerous formulation efforts that can be investigated, research especially on amorphous drugs and formulations appears to be a useful approach. Whilst few drugs can be converted to an amorphous form on their own, due to their physical stability, the use of amorphous solid dispersions, i.e., the dissolution of drug molecules into (amorphous) polymers is increasingly used. However, certain shortcomings of these polymers based amorphous solid dispersions, such as a low drug load and a usually high hygroscopicity, still necessitate the investigation of alternative approaches. One such approach is the use of co-amorphous systems, i.e., the combination of initially crystalline low molecular weight drugs and excipients. Usually, here, a 1:1 molar ratio is used, but this may not be the optimal mixing ratio. In this presentation, work on investigating the optimal ratio between drug and co-former will be presented and critically discussed.

AB - Most new low molecular weight chemical entities in pharmaceutical developments suffer from a low aqueous solubility, making oral delivery challenging. Despite the numerous formulation efforts that can be investigated, research especially on amorphous drugs and formulations appears to be a useful approach. Whilst few drugs can be converted to an amorphous form on their own, due to their physical stability, the use of amorphous solid dispersions, i.e., the dissolution of drug molecules into (amorphous) polymers is increasingly used. However, certain shortcomings of these polymers based amorphous solid dispersions, such as a low drug load and a usually high hygroscopicity, still necessitate the investigation of alternative approaches. One such approach is the use of co-amorphous systems, i.e., the combination of initially crystalline low molecular weight drugs and excipients. Usually, here, a 1:1 molar ratio is used, but this may not be the optimal mixing ratio. In this presentation, work on investigating the optimal ratio between drug and co-former will be presented and critically discussed.

U2 - 10.3390/IECP2020-08764

DO - 10.3390/IECP2020-08764

M3 - Journal article

VL - 78

JO - Proceedings

JF - Proceedings

SN - 2504-3900

IS - 1

M1 - 27

ER -

ID: 299529775